Citigroup’s Minerva Neurosciences NERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $21.2K | Sell |
6,328
-9,645
| -60% | -$41.3K | ﹤0.01% | 4981 |
|
|
2026
Q2 | $88.6K | Buy |
+15,973
| New | +$86.6K | ﹤0.01% | 4753 |
|
|
2025
Q4 | – | Sell |
-1
| Closed | -$2 | – | 6327 |
|
|
2025
Q3 | $2 | Buy |
+1
| New | +$2 | ﹤0.01% | 6024 |
|
|
2022
Q3 | – | Sell |
-2,125
| Closed | -$7K | – | 6162 |
|
|
2022
Q2 | $7K | Buy |
+2,125
| New | +$8.68K | ﹤0.01% | 5503 |
|
|
2021
Q3 | – | Sell |
-138
| Closed | -$3K | – | 6126 |
|
|
2021
Q2 | $3K | Sell |
138
-293
| -68% | -$6.31K | ﹤0.01% | 5925 |
|
|
2021
Q1 | $10K | Sell |
431
-539
| -56% | -$13.5K | ﹤0.01% | 5650 |
|
|
2020
Q4 | $18K | Buy |
970
+627
| +183% | +$15.8K | ﹤0.01% | 6720 |
|
|
2020
Q3 | $9K | Sell |
343
-350
| -51% | -$9.46K | ﹤0.01% | 6698 |
|
|
2020
Q2 | $20K | Sell |
693
-472
| -41% | -$27.7K | ﹤0.01% | 6610 |
|
|
2020
Q1 | $56K | Buy |
1,165
+298
| +34% | +$18K | ﹤0.01% | 5881 |
|
|
2019
Q4 | $49K | Buy |
867
+68
| +9% | +$3K | ﹤0.01% | 6325 |
|
|
2019
Q3 | $50K | Sell |
799
-458
| -36% | -$25.9K | ﹤0.01% | 6130 |
|
|
2019
Q2 | $57K | Buy |
1,257
+38
| +3% | +$1.9K | ﹤0.01% | 6348 |
|
|
2019
Q1 | $77K | Buy |
1,219
+228
| +23% | +$13.7K | ﹤0.01% | 5981 |
|
|
2018
Q4 | $53K | Sell |
991
-56
| -5% | -$4.1K | ﹤0.01% | 6188 |
|
|
2018
Q3 | $105K | Buy |
1,047
+398
| +61% | +$29.9K | ﹤0.01% | 5854 |
|
|
2018
Q2 | $43K | Sell |
649
-684
| -51% | -$41.5K | ﹤0.01% | 6395 |
|
|
2018
Q1 | $67K | Buy |
1,333
+15
| +1% | +$721 | ﹤0.01% | 5954 |
|
|
2017
Q4 | $63K | Buy |
1,318
+991
| +303% | +$49.1K | ﹤0.01% | 6011 |
|
|
2017
Q3 | $20K | Sell |
327
-31,306
| -99% | -$1.8M | ﹤0.01% | 6441 |
|
|
2017
Q2 | $2.24M | Buy |
31,633
+31,279
| +8,836% | +$2.02M | ﹤0.01% | 2472 |
|
|
2017
Q1 | $23K | Sell |
354
-881
| -71% | -$68.4K | ﹤0.01% | 6187 |
|
|
2016
Q4 | $116K | Buy |
1,235
+1,040
| +533% | +$106K | ﹤0.01% | 5685 |
|
|
2016
Q3 | $22K | Sell |
195
-7
| -3% | -$679 | ﹤0.01% | 6157 |
|
|
2016
Q2 | $16K | Sell |
202
-423
| -68% | -$26.9K | ﹤0.01% | 6283 |
|
|
2016
Q1 | $31K | Sell |
625
-1
| -0.2% | -$43 | ﹤0.01% | 6340 |
|
|
2015
Q4 | $30K | Buy |
+626
| New | +$26.1K | ﹤0.01% | 6263 |
|
|
2015
Q2 | – | Sell |
-105
| Closed | -$4K | – | 7663 |
|
|
2015
Q1 | $4K | Buy |
+105
| New | +$4.35K | ﹤0.01% | 6783 |
|
|
2014
Q4 | – | Sell |
-53
| Closed | -$3K | – | 7237 |
|
|
2014
Q3 | $3K | Buy |
+53
| New | +$2.82K | ﹤0.01% | 6731 |
|
Other funds holding NERV
Citigroup's NERV Position: Q3 2026 in Review
Citigroup reduced its Minerva Neurosciences (NERV) stake by 60% in Q3 2026, selling an estimated $41.3K and leaving 6,328 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4981.
Citigroup first reported a position in NERV in Q3 2014 and has held it in 29 quarters since. The position peaked at $2.24M in Q2 2017. 9 funds tracked by Wall St. Rank hold NERV as of Q3 2026.
- Citigroup held 6,328 shares of Minerva Neurosciences worth $21.2K as of Q3 2026.
- Citigroup sold 9,645 Minerva Neurosciences shares in Q3 2026, an estimated $41.3K.
- Minerva Neurosciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4981 holding.
- Citigroup first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 29 quarters since.
- Citigroup's Minerva Neurosciences position peaked at $2.24M in Q2 2017.
- 9 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.